Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if Telcyta® given in combination with
liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women
who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal
cancer that is refractory or resistant to platinum chemotherapy.